Previous 10 | Next 10 |
2023-08-05 12:28:15 ET Summary Pacira BioSciences posted mixed Q2 FY'23 earnings, with $34mm in quarterly FCF on $42mm pre-tax earnings. The company's EXPAREL unit sales were down YoY due to pricing issues from the 340B drug pricing program. Capital deployment and business ret...
2023-08-03 13:52:10 ET TD Cowen has upgraded its rating on Pacira Biosciences ( NASDAQ: PCRX ) to outperform, stating that it sees the stock set for a rebound in the latter half of the year amid upcoming catalysts. The investment bank said it believes the company's mixed Q2 earn...
2023-08-02 12:36:04 ET Pacira BioSciences, Inc. (PCRX) Q2 2023 Earnings Conference Call August 2, 2023, 08:30 AM ET Company Participants Susan Mesco - Head of IR David Stack - Chairman & CEO Charles Reinhart - CFO Conference Call Participants Davi...
2023-08-02 08:02:53 ET Pacira BioSciences press release ( NASDAQ: PCRX ): Q2 Non-GAAP EPS of $0.78 beats by $0.02 . Revenue of $169.5M (+0.1% Y/Y) misses by $5.48M . Adjusted EBITDA of $54.3 million. Pacira ended the second quarter of 2023 with cash, cash e...
-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter ...
2023-08-01 13:13:06 ET Pacira BioSciences ( NASDAQ: PCRX ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is $0.76 (+49.0% Y/Y) and the consensus Revenue Estimate is $174.98M (+3.3% Y/Y). Over the l...
TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2023. Following the release, the company will host a live conference call and ...
2023-06-27 07:00:00 ET Summary With the cost of living has increased dramatically, we're all seeking ways to increase our income. Getting double-digit yields with high-yield stocks is a risky proposition. However, exploiting human nature, we can safely generate higher yields w...
TAMPA, Fla., May 31, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2023 Jefferies Healthcare Conference at 9:30 AM ET on Wednesday, June 7, 2023 in New York. Live audio of the event can be acces...
2023-05-10 02:35:15 ET Summary Pacira BioSciences came in with a mixed quarter this week, with a miss vs. consensus at the bottom line. Zilretta sales were $24mm or 15% of total quarterly revenue. Longer term, PCRX does not appear to be creating additional market value from th...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...
2024-07-02 14:00:06 ET Oren Livnat from H.C. Wainwright issued a price target of $57.00 for PCRX on 2024-07-02 12:36:00. The adjusted price target was set to $57.00. At the time of the announcement, PCRX was trading at $21.91. The overall price target consensus is at $48...